Researchers at the University of Illinois Urbana-Champaign report that extracellular vesicles released into the bloodstream ...

Phosphorus, a key ingredient in fertilizers, is running out. The world's food systems depend on phosphorus mined from limited ...

Membrane depolarization promotes extracellular signal-regulated kinase activation and cell proliferation via phosphatidylserine dynamics.

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Scientists developed a drug that destroys a cancer protein rather than blocking it, cutting pancreatic tumor growth by half ...

The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA ...

Texas A&M scientists have unlocked new potential for astatine-211, a rare and short-lived element, as a highly precise cancer-fighting isotope. Its alpha emissions destroy tumor cells while sparing ...

The initial public offering (IPO) of Emmvee Photovoltaic Power Ltd, a leading manufacturer of solar photovoltaic (PV) modules ...

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potentia ...